Multiple sclerosis

Glatiramer acetate inhibits monocyte reactivity in vitro and in vivo

Martin S. Weber, Michaela Starck, Stefan Wagenpfeil, Edgar Meinl, Reinhard Hohlfeld, Cinthia Farina

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

It is widely assumed that glatiramer acetate (GA), an approved agent for the immunomodulatory treatment of multiple sclerosis, acts primarily as an antigen for T lymphocytes. Recent studies, however, indicated that in vitro, GA directly inhibits dendritic cells, a rare but potent type of professional antigen-presenting cell (APC). To investigate whether these in vitro observations are relevant to the actions of GA in vivo, we studied the effects of GA on monocytes, the major type of circulating APC. In a first series of experiments, we investigated the effects of GA on monocyte reactivity in vitro. Monocytes were stimulated with ligands for Toll-like receptor (TLR)-2 (peptidoglycan and lipoteichoic acid), TLR-4 [lipopolysaccharide (LPS)] and TLR-5 (flagellin), as well as two proinflammatory cytokines (interferon-γ and granulocyte-monocyte colony-stimulating factor). Monocyte activation was measured by induction of the surface markers signalling lymphocytic activation molecule (SLAM), CD25 and CD69 (detected by cytofluorometry), and by production of monocyte-derived tumour necrosis factor (TNF)-α (detected by enzyme-linked immunospot assay). GA had a broad inhibitory effect on all measures of monocyte reactivity, regardless of which stimulator was used. It is unlikely that this reflects a simple toxic effect, because monocyte viability and CD14 expression were unaffected. In a second series of experiments, we investigated the properties of monocytes cultured ex vivo from eight GA-treated multiple sclerosis patients, eight untreated multiple sclerosis patients and eight healthy subjects. We found that LPS-induced SLAM expression and TNF-α production were significantly reduced in monocytes from GA-treated patients compared with controls. These results demonstrate for the first time that GA inhibits monocyte reactivity in vitro and in vivo, significantly extending the current concept of the mechanism of action of GA.

Original languageEnglish
Pages (from-to)1370-1378
Number of pages9
JournalBrain
Volume127
Issue number6
DOIs
Publication statusPublished - Jun 2004

Fingerprint

Multiple Sclerosis
Monocytes
Antigen-Presenting Cells
Lipopolysaccharides
Toll-Like Receptor 5
In Vitro Techniques
Glatiramer Acetate
Tumor Necrosis Factor-alpha
Flagellin
Enzyme-Linked Immunospot Assay
Toll-Like Receptor 2
Toll-Like Receptor 4
Peptidoglycan
Poisons
Granulocyte Colony-Stimulating Factor
Dendritic Cells
Interferons
Healthy Volunteers
Cytokines
Ligands

Keywords

  • ex vivo assay
  • Glatiramer acetate
  • Immunotherapy
  • Monocyte
  • Multiple sclerosis

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Weber, M. S., Starck, M., Wagenpfeil, S., Meinl, E., Hohlfeld, R., & Farina, C. (2004). Multiple sclerosis: Glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain, 127(6), 1370-1378. https://doi.org/10.1093/brain/awh163

Multiple sclerosis : Glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. / Weber, Martin S.; Starck, Michaela; Wagenpfeil, Stefan; Meinl, Edgar; Hohlfeld, Reinhard; Farina, Cinthia.

In: Brain, Vol. 127, No. 6, 06.2004, p. 1370-1378.

Research output: Contribution to journalArticle

Weber, MS, Starck, M, Wagenpfeil, S, Meinl, E, Hohlfeld, R & Farina, C 2004, 'Multiple sclerosis: Glatiramer acetate inhibits monocyte reactivity in vitro and in vivo', Brain, vol. 127, no. 6, pp. 1370-1378. https://doi.org/10.1093/brain/awh163
Weber, Martin S. ; Starck, Michaela ; Wagenpfeil, Stefan ; Meinl, Edgar ; Hohlfeld, Reinhard ; Farina, Cinthia. / Multiple sclerosis : Glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. In: Brain. 2004 ; Vol. 127, No. 6. pp. 1370-1378.
@article{edcfe1cdda5d46ed95f66bb6609eebf1,
title = "Multiple sclerosis: Glatiramer acetate inhibits monocyte reactivity in vitro and in vivo",
abstract = "It is widely assumed that glatiramer acetate (GA), an approved agent for the immunomodulatory treatment of multiple sclerosis, acts primarily as an antigen for T lymphocytes. Recent studies, however, indicated that in vitro, GA directly inhibits dendritic cells, a rare but potent type of professional antigen-presenting cell (APC). To investigate whether these in vitro observations are relevant to the actions of GA in vivo, we studied the effects of GA on monocytes, the major type of circulating APC. In a first series of experiments, we investigated the effects of GA on monocyte reactivity in vitro. Monocytes were stimulated with ligands for Toll-like receptor (TLR)-2 (peptidoglycan and lipoteichoic acid), TLR-4 [lipopolysaccharide (LPS)] and TLR-5 (flagellin), as well as two proinflammatory cytokines (interferon-γ and granulocyte-monocyte colony-stimulating factor). Monocyte activation was measured by induction of the surface markers signalling lymphocytic activation molecule (SLAM), CD25 and CD69 (detected by cytofluorometry), and by production of monocyte-derived tumour necrosis factor (TNF)-α (detected by enzyme-linked immunospot assay). GA had a broad inhibitory effect on all measures of monocyte reactivity, regardless of which stimulator was used. It is unlikely that this reflects a simple toxic effect, because monocyte viability and CD14 expression were unaffected. In a second series of experiments, we investigated the properties of monocytes cultured ex vivo from eight GA-treated multiple sclerosis patients, eight untreated multiple sclerosis patients and eight healthy subjects. We found that LPS-induced SLAM expression and TNF-α production were significantly reduced in monocytes from GA-treated patients compared with controls. These results demonstrate for the first time that GA inhibits monocyte reactivity in vitro and in vivo, significantly extending the current concept of the mechanism of action of GA.",
keywords = "ex vivo assay, Glatiramer acetate, Immunotherapy, Monocyte, Multiple sclerosis",
author = "Weber, {Martin S.} and Michaela Starck and Stefan Wagenpfeil and Edgar Meinl and Reinhard Hohlfeld and Cinthia Farina",
year = "2004",
month = "6",
doi = "10.1093/brain/awh163",
language = "English",
volume = "127",
pages = "1370--1378",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Multiple sclerosis

T2 - Glatiramer acetate inhibits monocyte reactivity in vitro and in vivo

AU - Weber, Martin S.

AU - Starck, Michaela

AU - Wagenpfeil, Stefan

AU - Meinl, Edgar

AU - Hohlfeld, Reinhard

AU - Farina, Cinthia

PY - 2004/6

Y1 - 2004/6

N2 - It is widely assumed that glatiramer acetate (GA), an approved agent for the immunomodulatory treatment of multiple sclerosis, acts primarily as an antigen for T lymphocytes. Recent studies, however, indicated that in vitro, GA directly inhibits dendritic cells, a rare but potent type of professional antigen-presenting cell (APC). To investigate whether these in vitro observations are relevant to the actions of GA in vivo, we studied the effects of GA on monocytes, the major type of circulating APC. In a first series of experiments, we investigated the effects of GA on monocyte reactivity in vitro. Monocytes were stimulated with ligands for Toll-like receptor (TLR)-2 (peptidoglycan and lipoteichoic acid), TLR-4 [lipopolysaccharide (LPS)] and TLR-5 (flagellin), as well as two proinflammatory cytokines (interferon-γ and granulocyte-monocyte colony-stimulating factor). Monocyte activation was measured by induction of the surface markers signalling lymphocytic activation molecule (SLAM), CD25 and CD69 (detected by cytofluorometry), and by production of monocyte-derived tumour necrosis factor (TNF)-α (detected by enzyme-linked immunospot assay). GA had a broad inhibitory effect on all measures of monocyte reactivity, regardless of which stimulator was used. It is unlikely that this reflects a simple toxic effect, because monocyte viability and CD14 expression were unaffected. In a second series of experiments, we investigated the properties of monocytes cultured ex vivo from eight GA-treated multiple sclerosis patients, eight untreated multiple sclerosis patients and eight healthy subjects. We found that LPS-induced SLAM expression and TNF-α production were significantly reduced in monocytes from GA-treated patients compared with controls. These results demonstrate for the first time that GA inhibits monocyte reactivity in vitro and in vivo, significantly extending the current concept of the mechanism of action of GA.

AB - It is widely assumed that glatiramer acetate (GA), an approved agent for the immunomodulatory treatment of multiple sclerosis, acts primarily as an antigen for T lymphocytes. Recent studies, however, indicated that in vitro, GA directly inhibits dendritic cells, a rare but potent type of professional antigen-presenting cell (APC). To investigate whether these in vitro observations are relevant to the actions of GA in vivo, we studied the effects of GA on monocytes, the major type of circulating APC. In a first series of experiments, we investigated the effects of GA on monocyte reactivity in vitro. Monocytes were stimulated with ligands for Toll-like receptor (TLR)-2 (peptidoglycan and lipoteichoic acid), TLR-4 [lipopolysaccharide (LPS)] and TLR-5 (flagellin), as well as two proinflammatory cytokines (interferon-γ and granulocyte-monocyte colony-stimulating factor). Monocyte activation was measured by induction of the surface markers signalling lymphocytic activation molecule (SLAM), CD25 and CD69 (detected by cytofluorometry), and by production of monocyte-derived tumour necrosis factor (TNF)-α (detected by enzyme-linked immunospot assay). GA had a broad inhibitory effect on all measures of monocyte reactivity, regardless of which stimulator was used. It is unlikely that this reflects a simple toxic effect, because monocyte viability and CD14 expression were unaffected. In a second series of experiments, we investigated the properties of monocytes cultured ex vivo from eight GA-treated multiple sclerosis patients, eight untreated multiple sclerosis patients and eight healthy subjects. We found that LPS-induced SLAM expression and TNF-α production were significantly reduced in monocytes from GA-treated patients compared with controls. These results demonstrate for the first time that GA inhibits monocyte reactivity in vitro and in vivo, significantly extending the current concept of the mechanism of action of GA.

KW - ex vivo assay

KW - Glatiramer acetate

KW - Immunotherapy

KW - Monocyte

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=2942594278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942594278&partnerID=8YFLogxK

U2 - 10.1093/brain/awh163

DO - 10.1093/brain/awh163

M3 - Article

VL - 127

SP - 1370

EP - 1378

JO - Brain

JF - Brain

SN - 0006-8950

IS - 6

ER -